Arcturus Therapeutics (ARCT) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcturus Therapeutics (ARCT) has outperformed Pyxis Oncology (PYXS) over the past year, gaining 19.0% versus a loss of 62.3%. Over five years, ARCT leads with a -81.3% price change compared with -85.9% for PYXS. Pyxis Oncology is the larger company by market cap ($216.5 million vs $214.7 million), about 1.0 times the size.
Arcturus Therapeutics converts more of its revenue into profit, with a net margin of -80.2% versus -574.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | PYXS |
|---|---|---|
| Share price | $7.45 | $1.81 |
| Market cap | $214.73M | $216.49M |
| 1-day change | -1.97% | +7.74% |
| YTD return | +21.53% | +57.39% |
| 1-year return | +19.01% | -62.29% |
| 5-year return | -81.32% | -85.90% |
| EPS (TTM) | $-3.10 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $82.03M | $13.86M |
| Revenue growth (YoY) | -46.14% | -14.17% |
| Net income (latest FY) | $-65.78M | $-79.62M |
| Gross margin | — | 82.77% |
| Operating margin | -92.96% | -609.18% |
| Net margin | -80.19% | -574.55% |
| 52-week high | $17.96 | $5.55 |
| 52-week low | $5.50 | $1.03 |
| Distance from 52-week high | -58.52% | -67.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.12% | +354.14% |
| Average volume | 851.45K | 1.06M |
| Shares outstanding | 28.82M | 119.61M |
| Employees | 106 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARCT has outperformed PYXS by 81.3 percentage points over the past year.
- Arcturus Therapeutics is more profitable, keeping -80.2 cents of every revenue dollar as net income versus -574.5 cents for Pyxis Oncology.
- Pyxis Oncology grew revenue faster in its latest fiscal year (-14.17% vs -46.14%).
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
ARCT vs PYXS FAQ
Which is bigger, Arcturus Therapeutics or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $216.49M compared with $214.73M for Arcturus Therapeutics (ARCT).
Which stock has performed better over the past year, ARCT or PYXS?
ARCT returned +19.01% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.